Company intelligence / Profile preview

Endotx

Miami, Florida, United States

Ownership: Private
Development stage: Other

Overview

Endo-Tx is a biotechnology company focused on developing a functional cure for Type 1 Diabetes through advanced islet cell transplantation technologies. The company's core platform, the BioHub, is a bioengineered site designed to mimic the natural pancreas environment, allowing for the successful transplantation and long-term survival of insulin-producing cells without the need for chronic immunosuppression. By utilizing innovative encapsulation and oxygenation techniques, Endo-Tx aims to restore natural glucose regulation in patients. The company operates in close collaboration with the Diabetes Research Institute to translate cutting-edge regenerative medicine into clinical therapies.

Therapeutic areas: Endocrinology
Modalities: Cell therapyDeviceBiologic
Industry: Biotech

Partnerships

Diabetes Research Institute (DRI)University of Miami

Beyond the preview

Go deeper on Endotx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endotx.

Explore the full profile